Canada on Thursday authorized British drugmaker AstraZeneca Plc’s antibody-based therapy for preventing COVID-19 infections, giving itself another weapon against the disease as cases rise in the country. Health Canada has cleared the drug – Evusheld – for use in individuals aged 12 years and older who are immune compromised and unlikely to mount an adequate…
AstraZeneca’s Imfinzi Fails Main Goal in Advanced Cervical Cancer Study
AstraZeneca said on Thursday its drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening. The late-stage study, dubbed “CALLA,” tested progression-free survival of patients with the combination against chemoradiotherapy alone, the drugmaker said, and the results are seen as…
AstraZeneca COVID Drug Performs Well Against Omicron Subvariants: Study
A COVID-19 drug made by AstraZeneca did nearly as well against subvariants of the Omicron virus variant as the main variant, according to a new study. Researchers with AstraZeneca, the Washington University School of Medicine, and other institutions used mice to test the monoclonal antibody combination, known as Evusheld, and a drug made by Vir Biotechnology,…
AstraZeneca Pays $775 Million to Settle Drug Dispute With Japan’s Chugai
Anglo-Swedish drugmaker AstraZeneca Plc said on Thursday it would pay $775 million to settle a patent dispute with Japan’s Chugai Pharmaceutical involving lucrative rare disease treatment Ultomiris. Both AstraZeneca and Chugai will withdraw patent infringement cases filed in the United States and Japan dating back to 2018 as part of the settlement, the London-listed company…
Novavax Approved as Booster Alternative for Australians 18 and Over
The Novavax COVID-19 protein vaccine has been approved by the ATAGI as a booster alternative to mRNA vaccines for Australians aged 18 and over. The ATAGI stated (pdf) that the Novavax COVID-19 vaccine currently has “limited evidence” on its safety and immunogenicity as a booster, but is acceptable as a third shot if “no other COVID-19…
AstraZeneca Sees Higher 2022 Sales, but Forecasts COVID-19 Shot Revenues to Decline
British–Swedish multinational pharmaceutical company AstraZeneca on Thursday forecast higher sales in 2022 after posting a better-than-expected fourth-quarter profit. But the biotechnology company warned that it expects revenues to decline as sales of its COVID-19 products drop, and that the gross profit margins from those products would be lower than the company average. The drugmaker recorded full-year revenues…
Moderna, AstraZeneca Partnering To Develop an ‘mRNA Therapeutic’ For Heart Disease
Drugmakers Moderna and AstraZeneca are partnering up to develop a “mRNA therapeutic” to treat life-threatening cardiovascular disease such as heart failure. “We are collaborating with @AstraZeneca on an mRNA therapeutic (AZD8601) that encodes for VEGF-A to promote recovery of cardiac function through tissue regeneration,” Moderna said in a Twitter post Thursday. The biotechnology company included…
AstraZeneca Says Its COVID-19 Shot Given as Booster Works Against Omicron
AstraZeneca said its COVID-19 vaccine, called Vaxzevria, generated an antibody response against Omicron when given as a third booster dose to individuals who were earlier inoculated with either AstraZeneca’s shot or an mRNA jab. Citing preliminary data from an ongoing clinical trial, AstraZeneca said in a Jan. 13 statement that its COVID-19 vaccine generated an increased immune…
US Court Revives Lawsuit Against Pfizer, Others on Iraq Terrorism Funding Claims
A U.S. appeals court on Tuesday revived a lawsuit against AstraZeneca Plc, Pfizer Inc and other companies over allegations their contracts with Iraq’s health ministry helped fund terrorism that killed Americans during the war in Iraq. The plaintiffs contend that the militia group Jaysh al-Mahdi, sponsored by the terrorist group Hezbollah, controlled Iraq’s health ministry…
‘Commercial Interests Colliding With Public Health’ in COVID-19 Vaccine Industry: Researcher
Billions of dollars in government funding ploughed into COVID-19 vaccine research during the pandemic has helped push the boundaries of drug research beyond their usual limits in the race to create the jab, says lead researcher of the Spikogen (or COVAX-19) vaccine. Professor Nikolai Petrovsky says the pandemic has been a springboard for major drug…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`